



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C07D 209/08, A61K 31/40, C07D 403/12, 401/12, 413/12		A2	(11) International Publication Number: <b>WO 96/23769</b>
			(43) International Publication Date: 8 August 1996 (08.08.96)
(21) International Application Number: PCT/EP96/00369		(74) Agent: SUMMERSSELL, Richard, John; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).	
(22) International Filing Date: 24 January 1996 (24.01.96)		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data:  9502051.7 2 February 1995 (02.02.95) GB 9510254.7 20 May 1995 (20.05.95) GB		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): GASTER, Laramie, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). WYMAN, Paul, Adrian [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). MULHOLLAND, Keith, Raymond [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). DAVIES, David, Thomas [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).			
(54) Title: HETEROCYCLIC COMPOUNDS POSSESSING 5HT <sub>2C</sub> RECEPTOR ANTAGONIST ACTIVITY			
(57) Abstract  The invention relates to heterocyclic families of compounds having pharmacological activity, in particular possessing 5HT <sub>2C</sub> receptor antagonist activity processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.			

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## HETERO CYCLIC COMPOUNDS POSSESSING 5HT2C RECEPTOR ANTAGONIST ACTIVITY

5 This invention relates to compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

WO 95/01976 (SmithKline Beecham plc) describes indoline derivatives which are described as possessing 5HT<sub>2C</sub> receptor antagonist activity. A structurally distinct class of compounds has now been discovered, which have been found to have 5HT<sub>2C</sub> receptor antagonist activity. Certain compounds of the invention also exhibit 10 5HT<sub>2B</sub> antagonist activity. 5HT<sub>2C/2B</sub> receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also 15 disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS as well as microvascular diseases such as macular oedema and retinopathy.

20 The present invention therefore provides, in a first aspect, a compound of formula (I) or a salt thereof:



25 wherein:

P represents phenyl, a quinoline or isoquinoline residue, or a 5-membered or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;

30 R is hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, NR<sup>4</sup>COR<sup>5</sup>, C<sub>1-6</sub> alkylthio, cyano, nitro, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, NR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup>, CHO, COR<sup>6</sup>, CH<sub>2</sub>OR<sup>6</sup>, CO<sub>2</sub>R<sup>6</sup>, OR<sup>6</sup> or S(O)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup>, where n is 1 or 2 and R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, aryl or arylC<sub>1-6</sub>alkyl;


35 R<sup>1</sup> is hydrogen, X(CR<sup>8</sup>R<sup>9</sup>)<sub>p</sub>R<sup>10</sup> where X is a bond, oxygen, sulphur, C=O, CH=N-O, CONR<sup>7</sup> or NR<sup>7</sup> where R<sup>7</sup> is hydrogen or C<sub>1-6</sub> alkyl; R<sup>8</sup> and R<sup>9</sup> are independently hydrogen or C<sub>1-6</sub> alkyl; p is 0 to 6 and R<sup>10</sup> is hydroxy, C<sub>1-6</sub>alkoxy, NR<sup>4</sup>R<sup>5</sup> where R<sup>4</sup> and R<sup>5</sup> are as defined above for R, or R<sup>4</sup> and R<sup>5</sup> together form a

$C_2$  -  $C_6$  methylene chain optionally containing an O, S or  $NR^7$  group and optionally substituted by  $NR^4R^5$  or  $C_1$ - $C_6$  alkyl or  $NR^4R^5$  where  $R^4$  and  $R^5$  are independently  $C_1$ - $C_6$  alkyl, or one of  $R^4$  and  $R^5$  represents an optionally substituted alicyclic amine attached directly or via a  $C_1$ - $C_6$  alkyl group, or  $R^{10}$  is  $CO_2R^{11}$  where  $R^{11}$  is

5    hydrogen,  $C_1$ - $C_6$  alkyl or aryl;

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl;

$R^3$  is a group of formula (i):



10

in which:


X and Y are both nitrogen, one is nitrogen and the other is carbon or a  $CR^{12}$  group or one is a  $CR^{12}$  group and the other is carbon or a  $CR^{12}$  group;

15     $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  groups are independently hydrogen,  $C_1$ - $C_6$  alkyl optionally substituted by one or more halogen atoms,  $C_2$ - $C_6$  alkenyl,  $C_3$ - $C_6$  cycloalkyl,  $C_3$ - $C_6$  cycloalkyl- $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyloxy,  $C_3$ - $C_6$  cycloalkyl- $C_1$ - $C_6$  alkylthio,  $C_1$ - $C_6$  alkylthio,  $C_3$ - $C_6$  cycloalkylthio,  $C_3$ - $C_6$  cycloalkyl- $C_1$ - $C_6$  alkylthio,  $C_1$ - $C_6$  alkoxy, hydroxy, halogen, nitro,  $CF_3$ ,  $C_2F_5$ ,  $OCF_3$ ,  $SCF_3$ ,  $SO_2CF_3$ ,  $SO_2F$ , formyl,  $C_2$ - $C_6$  alkanoyl, cyano, optionally substituted phenyl or thienyl,  $NR^4R^5$ ,  $CONR^4R^5$  or  $CO_2R^6$  where  $R^4$ ,  $R^5$  and  $R^6$  are as defined for  $R^1$ ; or  $R^{14}$  and  $R^{15}$  form part of an optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring;

20     $R^{16}$  and  $R^{17}$  are independently hydrogen or  $C_1$ - $C_6$  alkyl; or

$R^3$  is a group of formula (ii):


25



(ii)

30    in which X and Y are both nitrogen, one is nitrogen and the other is a  $CR^{12}$  group or X and Y are both  $CR^{12}$  groups,  $R^{18}$  is hydrogen or  $C_1$ - $C_6$  alkyl, and  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are as defined in formula (I); or

$R^3$  is a group of formula (iii):



5

(iii)

in which  $R^{14}$ ,  $R^{15}$ , X and Y are as defined in formula (i) and Z is O, S,  $CH_2$  or  $NR^{19}$  where  $R^{19}$  is hydrogen or  $C_{1-6}$  alkyl.

$C_{1-6}$  Alkyl groups, whether alone or as part of another group, may be straight chain or branched.

10

The urea moiety can be attached to a carbon or any available nitrogen atom of the ring P, preferably it is attached to a carbon atom. Suitable moieties when the ring P is a 5-membered aromatic heterocyclic rings include isothiazolyl, isoxazolyl, thiadiazolyl and triazolyl. Suitable moieties when the ring P is a 6-membered aromatic heterocyclic rings include, for example, pyridyl, pyrimidyl or pyrazinyl.

15

When P is quinoline, or an isoquinoline residue, the urea moiety can be attached at any position of the ring, preferably to the 4- or 5-position. Preferably P is phenyl.

Suitably R is hydrogen,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $NR^4COR^5$ ,  $C_{1-6}$  alkylthio, cyano, nitro, halogen,  $CF_3$ ,  $OCF_3$ ,  $SCF_3$ ,  $C_2F_5$ ,  $NR^4R^5$ ,  $CONR^4R^5$ ,  $CHO$ ,  $COR^6$ ,  $CH_2OR^6$ ,  $CO_2R^6$ ,  $OR^6$  or  $S(O)_nNR^4R^5$ , where n is 1 or 2 and  $R^4$ ,  $R^5$  and  $R^6$  are independently hydrogen,  $C_{1-6}$  alkyl, aryl or aryl $C_{1-6}$ alkyl. Preferably R is hydrogen.


Suitably  $R^1$  is hydrogen,  $X(CR^8R^9)_pR^{10}$  where X is a bond, oxygen, sulphur,  $C=O$ ,  $CH=N-O$ ,  $CONR^7$  or  $NR^7$  where  $R^7$  is hydrogen or  $C_{1-6}$  alkyl;  $R^8$  and  $R^9$  are independently hydrogen or  $C_{1-6}$  alkyl; p is 0 to 6 and  $R^{10}$  is hydroxy,  $C_{1-6}$ alkoxy,  $NR^4R^5$  where  $R^4$  and  $R^5$  are as defined above for R or  $R^4$  and  $R^5$  together form a

$C_2-C_6$  methylene chain optionally containing an O, S or  $NR^7$  group and optionally substituted by  $NR^4R^5$  or  $C_{1-6}$  alkyl $NR^4R^5$  where  $R^4$  and  $R^5$  are independently  $C_{1-6}$  alkyl, or one of  $R^4$  and  $R^5$  represents an optionally substituted alicyclic amine attached directly or via a  $C_{1-6}$  alkyl group, or  $R^{10}$  is  $CO_2R^{11}$  where  $R^{11}$  is

hydrogen,  $C_{1-6}$  alkyl or aryl. Preferably  $R^1$  is  $CO_2R^{11}$  where  $R^{11}$  is hydrogen or  $C_{1-6}$  alkyl, or  $R^1$  is  $X(CH_2)_pR^{10}$  where X is a bond,  $CONH$  or oxygen, p is 1 to 3,  $R^{10}$  is OH or  $NR^4R^5$  where  $R^4$  and  $R^5$  are  $C_{1-6}$  alkyl, in particular methyl.

Preferably  $R^2$  is hydrogen.

Preferably  $R^3$  is a group of formula (i). Preferably  $R^3$  is an indoline group having the following formula:



Suitably R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup> and R<sup>15</sup> groups are independently hydrogen, C<sub>1</sub>-6 alkyl optionally substituted by one or more halogen atoms, C<sub>2</sub>-6 alkenyl, 5 C<sub>3</sub>-6 cycloalkyl, C<sub>3</sub>-6 cycloalkylC<sub>1</sub>-6alkoxy, C<sub>2</sub>-6 alkynyl, C<sub>3</sub>-6 cycloalkyloxy, C<sub>3</sub>-6 cycloalkyl-C<sub>1</sub>-6 alkyl, C<sub>1</sub>-6 alkylthio, C<sub>3</sub>-6 cycloalkylthio, C<sub>3</sub>-6 cycloalkyl-C<sub>1</sub>-6 alkylthio, C<sub>1</sub>-6alkoxy, hydroxy, halogen, nitro, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, SO<sub>2</sub>CF<sub>3</sub>, SO<sub>2</sub>F, formyl, C<sub>2</sub>-6 alkanoyl, cyano, optionally substituted phenyl or thienyl, NR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup> or CO<sub>2</sub>R<sup>6</sup> where R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined for 10 R<sup>1</sup>; or R<sup>14</sup> and R<sup>15</sup> form part of an optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring. Preferably R<sup>12</sup> and R<sup>13</sup> are both hydrogen. Preferred R<sup>14</sup> and R<sup>15</sup> groups include C<sub>1</sub>-6 alkyl, C<sub>1</sub>-6alkoxy, C<sub>1</sub>-6 alkylthio, halogen and CF<sub>3</sub>. Most preferably R<sup>14</sup> is trifluoromethyl and R<sup>15</sup> is C<sub>1</sub>-6alkoxy, in particular methoxy or C<sub>1</sub>-6 alkylthio, in particular methylthio.

15 Particular compounds of the invention include:

5-Methoxy-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

5-Methoxy-6-trifluoromethyl-1-[4-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

20 5-Methylthio-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

5-Methoxy-6-trifluoromethyl-1-[2-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-[3-(2-hydroxy)-ethoxyphenyl-carbamoyl]indoline,

25 5-Methylthio-6-trifluoromethyl-1-[3-ethoxycarbonylmethoxy) phenyl carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-[3-(3-hydroxypropyloxy)-phenyl-carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-[3-(2-dimethylaminoethyl)carbamoyl phenyl carbamoyl]indoline,

30 5-Methylthio-6-trifluoromethyl-1-[4-(2-dimethylaminoethyl)carbamoyl phenyl carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-(3-ethoxycarbonyl phenyl carbamoyl)indoline,

5-Methylthio-6-trifluoromethyl-1-(4-ethoxycarbonyl phenyl carbamoyl) indoline,

35 5-Methylthio-6-trifluoromethyl-1-(3-carboxy phenyl carbamoyl)indoline,

5-Methylthio-6-trifluoromethyl-1-(4-carboxy phenyl carbamoyl) indoline,  
5-Methylthio-6-trifluoromethyl-1-[3-(2-methoxy) ethoxy phenyl carbamoyl] indoline,  
5-Methylthio-6-trifluoromethyl-1-(3-ethoxyphenyl carbamoyl) indoline,  
5-Methylthio-6-trifluoromethyl-1-[3-(2-hydroxyethyl) amidophenyl carbamoyl]  
5 indoline,  
1-(3-(Dimethylaminomethyl)phenylcarbamoyl)-5-methylthio-6-  
trifluoromethylindoline,  
1-[3-[(2-Aminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl  
indoline,  
10 1-[3-[2-Diethylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
1-[3-[(2-Diisopropylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
1-[3-[(2-Dibutylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
15 trifluoromethyl indoline,  
1-[3-[(2-Dimethylaminoethyl)methylcarbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
1-[3-[(2-Dimethylaminopropyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
20 1-[3-[(2-Pyridylmethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl  
indoline,  
1-[3-[(3-Dimethylamino-2-propyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
1-[3-[(2-(N-Methyl-N-phenyl)ethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
25 trifluoromethyl indoline,  
1-[3-(4-Dimethylamino-1-oxobutyl)phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
1-[3-(N-methylpiperazinylcarbonyl)phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
30 1-[3-[(2-Piperid-1-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
1-[3-[(2-Morpholin-4-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,  
1-[3-[(N-Ethylpyrrolidin-2-ylmethyl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-  
35 trifluoromethyl indoline,  
1-[3-[(2-Pyrrolidin-1-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline,

1-[3-[(N-Benzylpyrrolidin-3-yl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
1-[3-[(2-Dimethylaminomethyl)pyrrolidin-1-yl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
5 1-[3-[(3-Dimethylaminopyrrolidin-1-yl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
1-[2-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
10 1-[2-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
1-[3-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
1-[3-(3-(Dimethylamino)propyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
15 1-[3-[(2-Dimethylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
1-[4-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
1-[4-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
20 1-[3-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
1-[3-(3-(Dimethylamino)propyloxy)phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
25 1-[3-[(2-(Dimethylamino)ethyloxy)iminomethyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
1-[Phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
1-(4-Hydroxymethylphenylcarbamoyl)-5-methylthio-6-trifluoromethyl indoline,  
1-[(5-Bromo-2-thienyl)carbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
30 1-[2-Thienylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
and pharmaceutically acceptable salts thereof.

The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, 35 mandelic, tartaric and methanesulphonic.


Compounds of formula (I) may also form N-oxides or solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or

5 any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

10 the coupling of a compound of formula (II);



15 with a compound of formula (III);



wherein P is as defined in formula (I), A and B contain the appropriate functional group(s) necessary to form the moiety  $-NR^{2'}CO$  when coupled, the variables R', R<sup>1'</sup> and R<sup>3'</sup> are R, R<sup>1</sup> and R<sup>3</sup> respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any R', R<sup>1'</sup> and R<sup>3'</sup>, when other than R, R<sup>1</sup> and R<sup>3</sup> respectively to R', R<sup>1</sup> and R<sup>3</sup>, interconverting R, R<sup>1</sup> and R<sup>3</sup> and forming a pharmaceutically acceptable salt thereof.

25 The above reactions can be carried out using procedures well known in the art, for example those disclosed in WO 95/01976.

Novel intermediates of formula (III) also form part of the invention.

30 Compounds of formula (I) can be converted into other compounds of formula (I) using standard procedures. For example compounds where R<sup>1'</sup> forms an ethyl ester can be hydrolysed to the corresponding carboxylic acid which can then be converted to amide derivatives via acid chloride formation.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative. N-oxides may be formed conventionally by reaction with hydrogen peroxide or percarboxylic acids.

35 Compounds of formula (I) and their pharmaceutically acceptable salts have 5HT<sub>2B/2C</sub> receptor antagonist activity and are believed to be of potential use for the treatment or prophylaxis of CNS disorders such as anxiety, depression, epilepsy,

obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.

5 Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS.

Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.

10 The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

15 In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of the above disorders.

The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or 25 suppositories. Orally administrable compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

30 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), 35 preservatives, and, if desired, conventional flavourings or colourants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be

either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the

5 stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.

10 Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

15 The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two

20 or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.

When administered in accordance with the invention, no unacceptable toxicological effects are expected with the compounds of the invention.

25 The following Descriptions and Examples illustrate the preparation of compounds of the invention.

**Description 1****1-(2-Dimethylaminoethoxy)-3-nitrobenzene**

To a stirred solution of 3-nitrophenol (5g, 36 mmol) in dimethylformamide (100 ml) at 0°C was added sodium hydride (1.029g, 80% dispersion in mineral oil, 34.3 mmol). After the effervescence had subsided 2-dimethylaminoethyl chloride was added (5.746g, 37.8 mmol). After 1 hour the reaction mixture was allowed to warm to room temperature. After a further 2 hours the reaction mixture was heated to 70°C for 14 hours, then evaporated under reduced pressure. The residue was then partitioned between water and ethyl acetate and the organic phase washed twice with aqueous sodium hydroxide solution (5M) and then saturated aqueous sodium chloride solution. Drying and evaporation gave the product as a brown oil (4.64g, 61%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.65 (2H, m, J 7Hz); 7.3 (1H, t, J 7Hz); 7.1 (1H, d, J 7Hz); 4.0 (2H, t, J 5Hz); 2.7 (2H, t, J 5Hz); 2.25 (6H, s).

**Description 2****3-(2-Dimethylaminoethoxy)aniline**

To a solution of 1-(2-dimethylaminoethoxy)-3-nitrobenzene (4.64g, 22 mmol) in ethanol (200 ml) was added 10% palladium catalyst on charcoal (1g). The reaction mixture was hydrogenated at atmospheric pressure for 2 hours, then filtered through kieselguhr and evaporated under reduced pressure to give the product as a yellow oil (4.0g, 100%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.0 (1H, t, J 7Hz); 6.25 (3H, m, J 7Hz); 4.0 (2H, t, J 6Hz); 3.7 (2H, s); 2.7 (2H, t, J 6Hz); 2.3 (6H, s).

**Description 3****1-(2-Dimethylaminoethoxy)-4-nitrobenzene**

Prepared in the same manner as 1-(2-dimethylaminoethoxy)-3-nitrobenzene to yield the product as a yellow oil (0.58g, 8%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 8.15 (2H, d, J 8Hz); 6.95 (2H, d, J 8Hz); 4.15 (2H, t, J 5Hz); 2.75 (2H, t, J 5Hz); 2.3 (6H, s).

**Description 4****4-(2-Dimethylaminoethoxy)aniline**

Prepared in the same manner as 1-(2-dimethylaminoethoxy)-3-nitrobenzene to yield  
5 the product as a yellow oil (0.43g, 86%).

10  $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$ : 6.75 (2H, d, J 8Hz); 6.6 (2H, d, J 8Hz); 3.95 (2H, t, J 5Hz); 3.4 (2H, s); 2.7 (2H, t, J 5Hz); 2.3 (6H, s).

**10 Description 5****1-(2-Dimethylamino)ethoxy-2-nitrobenzene**

To a stirred solution of 2-nitrophenol (5g, 36 mmol) in dimethylformamide (100 ml) was added potassium carbonate (9.94g, 72 mmol) and 2-dimethylaminoethyl chloride hydrochloride (7.78 g, 54 mmol). This was then heated to 60° C for 60 hours, then partitioned between half saturated aqueous sodium chloride and ethyl acetate. The organic phase was then washed four times with aqueous sodium hydroxide solution (5M), separated, dried and evaporated to give an orange solid. This was recrystallized from ethyl acetate affording the product as a yellow solid (1.43g, 19%).

20

10  $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$ : 7.8 (1H, d, J 7 Hz), 7.5 (1H, t, J 6 Hz), 7.1 (1H, d, J 7 Hz), 7.0 (1H, t, J 6 Hz), 4.2 (2H, t, J 5 Hz), 2.8 (2H, t, J 5Hz), 2.35 (6 H, s)

**Description 6****2-(2-Dimethylaminoethoxy)aniline**

This was prepared in the same manner as 3-(2-Dimethylaminoethoxy)aniline to yield the product as a dark yellow oil (1.02 g, 83%).

30

10  $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$ : 6.65 (4H, m), 4.0 (2H, t, J 5Hz), 3.85 (2H, s), 2.6 (2H, t, J 5Hz), 2.2 (6H, s)

**Description 7****1-t-Butyldimethylsilyloxy-2-iodoethane**

35

A mixture of 2-iodoethanol (12.4 g, 72 mmol) and tert-butyldimethylsilyl chloride (11.94 g, 79 mmol) in chloroform (10 ml) was treated with imidazole (5.39 g, 79 mmol) which produced a white suspension. This was filtered and washed with

chloroform. The filtrate was evaporated under reduced pressure to give the product as a colourless liquid (20.592g, 100%).

1H NMR (CDCl<sub>3</sub>) δ: 3.7 (2H, t, J 6 Hz), 3.1 (2H, t, J 6 Hz), 0.8 (9H, s), 0.0 (6H, s)

5

**Description 8**

**1-(2-t-Butyldimethylsilyloxyethoxy)-3-nitrobenzene**

To a stirred solution of 3-nitrophenol (5 g, 36 mmol) in dimethylformamide (100 ml) at 0° C was added sodium hydride (1.029g, 34.4 mmol). After effervescence had subsided 1-t-butyldimethylsilyl-2-iodoethane was added (10.811 g, 37.8 mmol) and the reaction mixture left at room temperature for 18 hours. Potassium carbonate (2 g) was added and the mixture heated at 100° C for 2 h. It was then quenched with saturated aqueous ammonium chloride solution and evaporated under reduced pressure. The residue was then partitioned between water and ethyl acetate and the organic extract washed with saturated aqueous sodium chloride solution twice, before being separated, dried, and evaporated under reduced pressure to give the crude product as a brown oil (9.697 g, 91%). This was chromatographed on silica eluting with 0-15% ethyl acetate/petroleum ether to give the product as a yellow oil (7.918 g, 20 74%)

1H NMR (CDCl<sub>3</sub>) δ: 7.7 (1H, d, J 7 Hz), 7.6 (1H, s), 7.3 (1H, t, J 8 Hz), 7.1 (1H, d, J 7 Hz), 4.0 (2H, t, J 5 Hz), 3.9 (2H, t, J 5 Hz), 0.8 (9H, s), 0.0 (6H, s).

25 **Description 9**

**3-(2-t-Butyldimethylsilyloxyethoxy)aniline**

To a solution of 1-(2-t-butyldimethylsilyloxyethoxy)-3-nitrobenzene (7.918 g, 27 mmol) in ethanol (150 ml) was added 10% palladium catalyst on charcoal (2 g) and the reaction mixture was hydrogenated at atmospheric pressure for 2 hours. It was then filtered through kieselguhr and evaporated under reduced pressure to yield the product as a yellow oil (6.707 g, 94%)

1H NMR (CDCl<sub>3</sub>) δ: 6.9 (1H, t, J 7 Hz), 6.15 (3H, m), 3.85 (4H, m), 3.5 (2H, s), 0.8

35 (9H, s), 0.0 (6H, s)

**Description 10**

**5-Methylthio-6-trifluoromethyl-1-{3-[O-(2-tert-butyldimethylsilyloxy)ethyl]phenylcarbamoyl}indoline**

5 To a stirred solution of carbonyldiimidazole (0.681 g, 4.2 mmol) in dichloromethane (10 ml) was added, dropwise, a solution of O-(2-tert-butyldimethylsilyloxy)ethyl-3-aminophenol (1.068 g, 4 mmol) in dichloromethane (10 ml). After 1 hour the reaction mixture was evaporated to dryness. The residue was then treated with 5-methylthio-6-trifluoromethyl indoline (0.933 g, 4 mmol) and dimethylformamide (10 ml) and heated to 100° C for 1 hour. Water was added to give a white precipitate which was filtered to give the crude product as a white solid (1.576 g, 75%). This was then chromatographed on silica eluting with 0-5% ethyl acetate/petroleum ether to give the product as a white solid (0.705 mg, 34%).

10 15  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 8.2 (1H, s), 7.1 (1H, t,  $J$  7 Hz), 7.0 (1H, s), 6.85 (1H, d,  $J$  7 Hz), 6.55 (1H, s,  $J$  7 Hz), 6.25 (1H, s), 4.0 (2H, t,  $J$  7 Hz), 3.9 (4H, m), 3.2 (2H, t,  $J$  7 Hz), 2.9 (3H, s), 0.8 (9H, s), 0.0 (6H, s)

**Description 11**

20 **Ethyl(3-nitrophenoxy)acetate**

This was made in the same manner as Description 1 to yield the product as a yellow oil (7.716g, 95%).

25  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 7.8 (1H, d,  $J$  7 Hz), 7.7 (1H, s), 7.4 (1H, t,  $J$  7 Hz), 7.2 (1H, d,  $J$  7 Hz), 4.7 (2H, s), 4.2 (2H, q,  $J$  7 Hz), 1.2 (3H, t,  $J$  7 Hz)

**Description 12**

**Ethyl(3-aminophenoxy)acetate**

30

This was made in the same manner as Description 2 to yield the product as a dark yellow oil (6.25g, 93%)

35  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 7.0 (1H, t,  $J$  7 Hz), 6.2 (3H, m), 4.5 (2H, s), 4.2 (2H, q,  $J$  7 Hz), 3.7 (2H, s), 1.3 (3H, t, 7 Hz)

**Description 13****1-(3-t-Butyldimethylsilyloxypropyloxy)-3-nitrobenzene**

This was prepared in the same manner as Description 8 to yield the product as a  
5 yellow oil (5.5g, 55%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 7.95 (1H, d,  $J$  7 Hz), 7.9 (1H, s), 7.6 (1H, t,  $J$  7 Hz), 7.4 (1H, d,  $J$  7 Hz), 4.3 (2H, t,  $J$  5 Hz), 4.0 (2H, t,  $J$  5 Hz), 2.2 (2H, qn,  $J$  5 Hz), 1.1 (9H, s), 0.0 (6H, s).

10

**Description 14****3-(3-t-Butyldimethylsilyloxypropyloxy)aniline**

This was prepared in the same manner as Description 9 to yield the product as a dark  
15 yellow oil (4.51g, 91%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 7.05 (1H, t,  $J$  7 Hz), 6.3 (3H, m), 4.0 (2H, t,  $J$  5 Hz), 3.8 (2H, t,  $J$  5 Hz), 3.7 (2H, s), 2.0 (2H, q), 0.9 (9H, s), 0.0 (6H, s).

20 **Description 15****5-Methylthio-6-trifluoromethyl-1-[3-(3-tert-butyldimethylsilyloxypropyloxy)phenyl carbamoyl]indoline**

This was prepared in the same manner as 5-methylthio-6-trifluoromethyl-1-[3-[O-(2-  
25 tert-butyldimethylsilyloxy)ethyl]phenylcarbamoyl]indoline to give the product as a  
white solid (0.85g, 44%).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 8.31 (1H, s), 7.2 (1H, t,  $J$  7 Hz), 7.1 (1H, s), 6.9 (1H, d,  $J$  7 Hz), 6.6 (1H, d,  $J$  7 Hz), 6.3 (1H, s), 4.0 (4H, m), 3.75 (2H, t,  $J$  5 Hz), 3.2 (2H, t,  $J$  7 Hz), 2.4 (3H, s), 1.9 (2H, qn,  $J$  5 Hz), 0.9 (9H, s), 0.0 (6H, s).

**Description 16****6-Trifluoromethylindoline (D16)**

35 6-Trifluoromethylindole<sup>1</sup> (5.27g, 28.5 mmol) in glacial acetic acid (50 ml) was  
treated with sodium cyanoborohydride (3.60g, 57.0 mmol) portionwise at room  
temperature with stirring. After 3 h at room temperature the reaction mixture was  
diluted with water (100 ml) and basified with 40% aqueous NaOH with cooling. The

mixture was then extracted with dichloromethane (3 x 150 ml) and the combined extracts were dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated to give the title compound (4.83g, 91%) as a brown solid.

5 NMR ( $\text{CDCl}_3$ )  $\delta$ : 3.07 (2H, t), 3.62 (2H, t), 6.80 (1H, s), 6.92 (1H, d,  $J$  = 8), 7.15 (1H, d,  $J$  = 8).

1. A.N. Tischler and T.J. Lanza, *Tet. Lett.* 1986, 26, 1653.

Description 17

10 5-Thiocyanato-6-trifluoromethylindoline (D17)

A mixture of 6-trifluoromethylindoline (D16) (9.7g, 52 mmol) and potassium thiocyanate (10.09g, 104 mmol) in methanol (200 ml) was treated with a solution of bromine (2.82 ml, 55 mmol) in methanol (35 ml) dropwise over 0.5 h at -5-0°C. The 15 reaction mixture was allowed to warm to room temperature and stirred overnight then evaporated to dryness. The residue was partitioned between aqueous  $\text{K}_2\text{CO}_3$  (100 ml) and dichloromethane (3 x 100 ml). The combined extracts were dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated and the residue chromatographed on silica using 2-30% ethyl acetate/petroleum ether as eluant to afford the title compound (9.1g, 72%) as a yellow 20 solid.

NMR ( $\text{CDCl}_3$ )  $\delta$ : 3.12 (2H, t,  $J$  = 8), 3.72 (3H, t,  $J$  = 8), 4.23 (1H, br s), 6.89 (1H, s), 7.50 (1H, s).

25 Description 18

Di[5-(6-trifluoromethylindoliny)]disulphide (D18)

The thiocyanate (D17) (28.5g, 0.116 mol) in dioxane (200 ml) and water (100 ml) was treated with aqueous ammonia (880, 200 ml) at 90°C for 1 h. The mixture was 30 cooled and evaporated to give a residue which was partitioned between water (300 ml) and dichloromethane (4 x 300 ml). The combined extracts were dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated to give the title compound (25.5g, 100%) as a yellow solid.

NMR ( $\text{CDCl}_3$ )  $\delta$ : 3.03 (2H, t,  $J$  = 8), 3.67 (2H, t,  $J$  = 8), 4.00 (1H, br s), 6.80 (1H, s), 35 7.49 (1H, s).

**Description 19****Di-[S-(1-acetyl-6-trifluoromethylindolinyl)]disulphide (D19)**

The disulphide (D18) (26g, 0.119 mol) in dichloromethane (300 ml) and 5 triethylamine (47.3 ml, 0.339 mol) was treated dropwise with a solution of acetic anhydride (22.5 ml, 0.238 mol) in dichloromethane (50 ml) at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h then poured into 2.5 M aqueous HCl (400 ml). The organic layer was separated and the aqueous was further extracted with dichloromethane (200 ml). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) 10 and evaporated to give the title compound (29.1g, 94%) as a yellow solid.

NMR (CDCl<sub>3</sub>) δ: 2.22 (3H, s), 3.21 (2H, t, J = 8), 4.10 (2H, t, J = 8), 7.68 (1H, s), 8.47 (1H, s).

**15 Description 20****1-Acetyl-5-mercaptop-6-trifluoromethylindoline (D20)**

A mixture of the diacetyl disulphide (D19) (28.5 g, 54.8 mmol), triphenylphosphine (20.85g, 79.5 mmol) and conc. aqueous HCl (1 ml) in dioxane (300 ml) and water (75 20 ml) was heated at reflux for 1.5 h. The reaction mixture was cooled and evaporated to a residue which was partitioned between dichloromethane (300 ml) and 1% aqueous NaOH (300 ml). The organic phase was further extracted with 1% aqueous NaOH (200 ml) and the combined aqueous fractions carefully acidified and extracted with dichloromethane (3 x 300 ml). The combined organic extracts were dried 25 (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to afford the title compound (26g, 91%) as a yellow solid.

NMR (CDCl<sub>3</sub>) δ: 2.24 (3H, s), 3.20 (2H, t, J = 8), 3.68 (1H, m), 4.11 (2H, t, J = 8), 7.22 (1H, s), 8.51 (1H, s).

**30 Description 21****1-Acetyl-5-methylthio-6-trifluoromethylindoline (D21)**

A mixture of the thiol (D20) (26g, 99 mmol), anhydrous K<sub>2</sub>CO<sub>3</sub> (15.12 g, 109 mmol) and iodomethane (18.6 ml, 300 mmol) in dry DMF (100 ml) was heated at 80° C for 35 1 h. The reaction mixture was cooled, evaporated *in vacuo* and partitioned between water (200 ml) and dichloromethane (3 x 200 ml). The combined organics were washed with water (400 ml), dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to yield the title compound (26.3g, 97%) as a yellow oil.

NMR (CDCl<sub>3</sub>) δ: 2.22 (3H, s), 2.49 (3H, s), 3.24 (2H, t, J = 8), 4.12 (2H, t, J = 8), 7.23 (1H, s), 8.51 (1H, s).

5    **Description 22**

**5-Methylthio-6-trifluoromethylindoline (D22)**

**Method (a)**

10    The acetyl indoline (D21) (26.3g, 95 mmol) was treated with NaOH (30g, 750 ml) in water (150 ml) and ethanol (200 ml) at reflux for 1.5 h. The reaction mixture was cooled, diluted with water (200 ml) and most of the ethanol evaporated *in vacuo*. The remaining mixture was extracted with dichloromethane (3 x 200 ml) and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to afford the title compound (21.9g, 99%) as a yellow oil.

15

NMR (CDCl<sub>3</sub>) δ: 2.41 (3H, s), 3.07 (2H, t, J = 8), 3.63 (2H, t, J = 8), 3.90 (1H, br s), 6.88 (1H, s), 7.30 (1H, s).

**Method (b)**

20

A stirred solution of potassium thiocyanate (38.6g, 0.39 mol) in methanol (470 ml) at -2° C under argon was treated dropwise over 10 minutes with bromine (10.3 ml, 0.195 mol) giving a yellow precipitate. The reaction mixture was stirred at 0° C for a further 15 minutes, then treated with a solution of

25

6-trifluoromethylindoline (D16) (33.2g, 0.177 mol) in methanol (320 ml) and allowed to warm to room temperature and stir for 4 h. A solution of potassium hydroxide (49.5g, 0.88 mol) in water (300 ml) was added in one portion; causing temperature to rise to 43° C and a brown solution to be produced. The mixture was stirred at 43-45° C for 25 minutes, then cooled to 12° C and treated with iodomethane (10.9 ml, 0.177 mol). The resulting mixture was allowed to warm to room temperature and stirred for 1.5 h, then concentrated *in vacuo* to approx. 350 ml volume. The residual aqueous mixture was extracted with dichloromethane (2 x 400ml) and the combined extract dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo* to give a brown oil (43 g), which was chromatographed on silica gel eluting with dichloromethane to afford the title compound (D22) as a light brown solid (25.3g, 61%) with spectral properties identical to those described above.

**Description 23****N,N-Dimethyl-3-nitrobenzamide (D23)**

3-Nitrobenzoyl chloride (1.03g, 5.5 mmol) was treated with dimethylamine (40% aqueous solution) (5 ml). The reaction mixture was stirred under Argon for 2 hours, and then extracted with dichloromethane (70 ml). The organic extract was dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated *in vacuo* to afford the title compound as a pale yellow solid (0.94g, 87%).

10  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$ (ppm): 8.29 (m, 2H), 7.79 (m, 1H), 7.62 (m, 1H), 3.15 (s, 3H), 3.0 (s, 3H)

**Description 24****N,N-Dimethyl-3-aminobenzamide (D24)**

15 N,N-Dimethyl-3-nitrobenzamide (D23) (0.94g, 4.8 mmol) was hydrogenated in ethanol (100 ml) over 10% Palladium-Charcoal (0.25g) for 1 hour. The catalyst was removed by filtration through Kieselguhr, and the filtrate concentrated *in vacuo* to afford the title compound as a light brown solid (0.68g, 87%).

20  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$ (ppm): 7.15 (m, 1H), 6.70 (m, 3H), 3.75 (b, 2H), 3.09 (s, 3H), 2.95 (s, 3H)

**Description 25****3-(N,N-Dimethylaminomethyl)aniline (D25)**

A stirred suspension of lithium aluminium hydride (0.24g, 6.3 mmol) in tetrahydrofuran (THF) (15 ml) at 0° C under Argon, was treated dropwise over a period of fifteen minutes, with a solution of N,N-Dimethyl-3-aminobenzamide (D24) (0.68g, 4.2 mmol) in THF (15 ml). The reaction mixture was allowed to warm to room temperature after which it was heated to reflux for 2 hours. The reaction mixture was allowed to cool to room temperature then treated sequentially with water (0.24 ml), 10% sodium hydroxide solution (0.24 ml) then water (0.72 ml). The reaction mixture was filtered through kieselguhr and the filtrate dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated *in vacuo* to afford the title compound as a pale brown oil (0.55g, 87%).

$^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$ (ppm): .10 (m, 1H), 6.62 (m, 3H), 3.24 (b, 2H), 3.32 (s, 2H), 2.22 (s, 6H).

**Description 26****1-Methoxy-4-nitro-2-trifluoromethylbenzene (D26)**

5     Sodium (11.78g, 0.512 mol) was dissolved in dry methanol (1 l) and to the resulting solution was added a solution of 1-chloro-4-nitro-2-trifluoromethyl-benzene (96.22g, 0.427 mol) in methanol (100 ml). The reaction mixture was refluxed for 3 h then cooled and evaporated *in vacuo*. The residue was partitioned between water (500 ml) and dichloromethane (3 x 400 ml). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to give the title compound (93.76g, 99%) as a white solid.

10

NMR (CDCl<sub>3</sub>) δ: 4.05 (3H, s), 7.12 (1H, d, J = 9), 8.45 (1H, dd, J = 3,9), 8.52 (1H, d, J = 3).

15    **Description 27**

**(5-Methoxy-2-nitro-4-trifluoromethylphenyl)acetonitrile (D27)**

A mixture of 1-methoxy-4-nitro 2-trifluoromethylbenzene (D26) (93g, 0.421 mol) and 4-chlorophenoxyacetonitrile (77.55g, 0.463 mol) in dry DMF (500 ml) was added dropwise over 0.75 h to a stirred solution of KO<sup>t</sup>Bu (103.85g, 0.927 mol) in dry DMF (400 ml) at -10° C. After complete addition the resulting purple solution was maintained at -10° C for 1 h then poured into a mixture of ice/water (1.5 l) and 5 M aqueous HCl (1.5 l). The resulting mixture was extracted with dichloromethane (3 x 1 l). The combined extracts were washed with water (3 l), dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated under reduced pressure. The residue was chromatographed on silica using 10-40% ethyl acetate/petroleum ether as eluant to give the crude product which was recrystallised from ethyl acetate/petroleum ether to afford the title compound (85.13g, 78%) as a white solid. Mp 103-104 °C.

20

25

30    NMR (CDCl<sub>3</sub>) δ: 4.10 (3H, s), 4.37 (2H, s), 7.34 (1H, s), 8.53 (1H, s).

**Description 28****5-Methoxy-6-trifluoromethylindole (D28)**

35    (5-Methoxy-2-nitro-4-trifluoromethylphenyl)acetonitrile (D27) (85g, 0.327 mol) in ethanol/water (9:1, 1.6 l) and glacial acetic acid (16 ml) was hydrogenated over 10% palladium on carbon (50 g) at 50 psi for 0.5 h at room temperature. The reaction mixture was filtered and evaporated *in vacuo*. The residue was partitioned between

aqueous  $K_2CO_3$  (1 l) and dichloromethane (2 x 1 l) and the combined organic extract was dried ( $Na_2SO_4$ ) and evaporated to afford the title indole (67.63g, 96%) as a grey solid.

5 NMR ( $CDCl_3$ )  $\delta$ : 3.94 (3H, s), 6.53 (1H, m), 7.21 (1H, s), 7.32 (1H, m), 7.64 (1H, s), 8.25 (1H, br s).

#### Description 29

##### 5-Methoxy-6-trifluoromethylindoline (D29)

10 The indole (D28) (67.63g, 0.315 mol) was treated with sodium cyanoborohydride (40 g, 0.637 mol) in glacial acetic acid (500 ml) as in the method of Description 16 to afford the title indoline (67.73g, 99%) as an off-white solid.

15 NMR ( $CDCl_3$ )  $\delta$ : 3.07 (2H, t,  $J$  = 8), 3.58 (2H, t,  $J$  = 8), 3.67 (1H, br s), 3.83 (3H, s), 6.83 (1H, s), 6.88 (1H, s).

#### Description 30

##### 3-Nitrobenzaldehyde oxime (D30)

20 3-Nitrobenzaldehyde (6g, 40 mmol) was added to a solution of hydroxylamine (15g, 216 mmol) in 5% aqueous sodium hydroxide solution (120 ml). Filtration and drying afforded the title compound as a white solid (5.23g, 79%).

25 NMR ( $CDCl_3$ ): 7.60 (1H, t), 7.80 (1H, s), 7.90 (1H, d), 8.20 (2H, m), 8.45 (1H, m)

#### Description 31

##### 3-Nitrobenzaldehyde-O-dimethylaminopropyl oxime (D31)

30 Sodium hydride (0.54g of 80% dispersion in oil, 18.8 mmol) was added to oxime D30 (3g, 18 mmol) at 0°C in N,N-dimethylformamide (50 ml). After 0.25 h 3-dimethylaminopropyl chloride (2.13g, 20 mmol) was added. The mixture was stirred at room temperature for 2 days then subjected to extractive workup and chromatography, affording the title oxime ether as a yellow oil (0.6g, 15%).

35 NMR ( $CDCl_3$ ): 2.30 (6H, s), 2.70 (2H, t), 4.30 (2H, t), 7.55 (1H, t), 7.90 (1H, d), 8.20 (2H, m), 8.55 (1H, m)

**Description 32****3-Aminobenzaldehyde-O-dimethylaminopropyl oxime (D32)**

5 A solution of oxime ether D31 (0.3g, 1.3 mmol) in ethanol (25 ml) was hydrogenated over platinum oxide (30 mg) for 0.5 h. Filtration and evaporation afforded the title aniline as a yellow oil (0.23g, 88%).

NMR (CDCl<sub>3</sub>): 2.30 (6H, s), 2.65 (2H, t), 3.70 (2H, bs), 4.25 (2H, t), 6.15 (1H, m), 6.90 (2H, m), 7.15 (1H, t), 8.05 (1H, s).

10

**Description 33****2-[2-(Dimethylamino)ethyl]aniline (D33)**

15 The title compound was prepared from 2-nitrophenylacetic acid by conversion to the N,N-dimethylamide, hydrogenation then reduction with lithium aluminium hydride.

**Example 1****5-Methoxy-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenyl]-carbamoyl]indoline**

20

To a stirred solution of carbonyldiimidazole (0.28g, 1.6 mmol) in dichloromethane (5 ml) was added, dropwise over 5 minutes, a solution of 3-(2-dimethylaminoethoxy)aniline (0.288g, 1.6 mmol) in dichloromethane (5 ml). After 1 hour the reaction mixture was evaporated to dryness under reduced pressure.

25

The residue was then treated with 5-methoxy-6-trifluoromethyl indoline (0.35g, 1.6 mmol) and dimethylformamide (20 ml) and heated to 100° C for 1 hour. Water was added and the precipitate was filtered and dried to give the product as a white solid (0.35g, 52%), m.p. 155-7°C.

30

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 8.2 (1H, s), 7.15 (2H, m), 6.9 (1H, d, J 7Hz), 6.8 (1H, s), 6.65 (1H, d, J 7Hz), 6.3 (1H, s), 4.05 (4H, m), 3.8 (3H, s), 3.25 (2H, t, J 8Hz), 2.8 (2H, t, J 5Hz), 2.3 (6H, s).

**Example 2**

**5-Methoxy-6-trifluoromethyl-1-[4-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline**

5 Prepared in the same manner as 5-methoxy-6-trifluoro-methyl-1-[3-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline to give the product as a white crystalline solid (100 mg, 16%). m.p. 172-4°C.

10  $^1\text{H}$  NMR (CDCl<sub>3</sub>) δ: 8.2 (1H, s); 7.25 (2H, d, J8Hz); 6.9 (2H, d, J8Hz); 6.85 (1H, s); 6.25 (1H, s); 4.05 (4H, m); 3.85 (3H, s); 3.3 (2H, t, J7Hz); 2.7 (2H, t, 5Hz); 2.3 (6H, s)

m/e 423

C<sub>21</sub>H<sub>24</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> requires 423

15

**Example 3**

**5-Methylthio-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline**

20 This was produced in the same manner as 5-methoxy-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline, using 5-methylthio-6-trifluoromethyl indoline in place of 5-methoxy-6-trifluoromethyl indoline, to yield the product as a brown solid (0.458g, 65%), m.p. 155-7°C.

25  $^1\text{H}$  NMR (CDCl<sub>3</sub>) δ: 8.3 (1H, s); 7.2 (3H, m); 6.9 (1H, d, J 7 Hz); 6.7 (1H, d, J 7 Hz); 6.4 (1H, s); 4.1 (4H, m); 3.3 (2H, t, J 7Hz); 2.7 (2H, t, J 5Hz); 2.45 (3H, s); 2.3 (6H, s).

**Example 4**

30 **5-Methoxy-6-trifluoromethyl-1-[2-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline**

35 This was prepared in the same manner as 5-methoxy-6-trifluoromethyl-1-[3-(2-dimethylamino) ethoxyphenyl carbamoyl]indoline to give the product as a white solid (0.196g, 29%), m.p. 155-7°C.

$^1\text{H}$  NMR (CDCl<sub>3</sub>) δ: 8.25 (2H, m), 7.8 (1H, s), 6.95 (3H, m), 6.85 (1H, s), 4.15 (4H, m), 3.85 (3H, s), 3.3 (2H, t, J 7 Hz), 2.7 (2H, t, J 5 Hz), 2.3 (6H, s)

**Example 5****5-Thiomethyl-6-trifluoromethyl-1-[3-(2-hydroxy)-ethoxyphenyl-carbamoyl]indoline**

To a stirred solution of 5-thiomethyl-6-trifluoromethyl-1-[3-[O-(2-tert-butyldimethylsilyloxy)ethyl]phenyl carbamoyl]indoline (0.705 g, 1.34 mmol) in tetrahydrofuran (5 ml) was added tetra-n-butylammonium fluoride in tetrahydrofuran (1M) solution (2 ml, 2 mmol). After 1 hour saturated aqueous ammonium chloride solution was added and the reaction mixture partitioned between ethyl acetate/water. The organic extract was washed once with water and once with saturated aqueous sodium chloride solution before being dried with anhydrous sodium sulphate, filtered and evaporated under reduced pressure to give the product as a white solid (0.465 g, 86%), m.p. 155-6° C.

<sup>1</sup>H NMR (DMSO) δ: 8.6 (1H, s), 8.2 (1H, s), 7.45 (1H, s), 7.25 (1H, s), 7.15 (2H, m), 6.6 (1H, d, J 5 Hz), 4.9 (1H, t, J 5 Hz), 4.2 (2H, t, J 7 Hz), 3.95 (2H, t, J 4 Hz), 3.7 (2H, q, J 4 Hz), 3.25 (2H, t, J 7 Hz), 2.5 (3H, s).

20

m/e 412

C<sub>19</sub>H<sub>19</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>S requires 412**Example 6****25 5-Methylthio-6-trifluoromethyl-1-[3-ethoxycarbonylmethoxy) phenyl carbamoyl]indoline**

This was prepared in the same manner as 5-methoxy-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenylcarbamoyl]indoline to yield the product as a white solid (0.38g, 16%) mp. 120-2° C.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 8.3 (1H, s), 7.65 (3H, m), 6.9 (1H, d, J7Hz), 6.6 (1H, d, J 7 Hz), 6.4 (1H, s), 4.6 (2H, s), 4.25 (2H, q, J 7 Hz), 4.05 (2H, t, J 7 Hz), 3.25 (2H, t, J 7 Hz), 2.45 (3H, s), 1.3 (3H, t, J 7 Hz).

35 C<sub>21</sub>H<sub>21</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S requires 454

**Example 7**

**5-Methylthio-6-trifluoromethyl-1-[3-(3-hydroxypropyloxy)-phenyl-carbamoyl]indoline**

5 This was prepared in the same manner as 5-methylthio-6-trifluoromethyl-1-[3-(2-hydroxy)-ethoxyphenyl-carbamoyl]indoline to give the product as a white solid (0.205g, 31%) mp. 166-8° C.

10  $^1\text{H}$  NMR (DMSO)  $\delta$ : 8.55 (1H, s), 8.2 (1H, s), 7.45 (1H, s), 7.25 (1H, d, J 7 Hz), 7.15 (2H, m), 6.6 (1H, s), 4.5 (1H, t, J 5 Hz), 4.15 (2H, t, J 7 Hz), 3.95 (2H, t, J 5 Hz), 3.5 (2H, t, J 5 Hz), 3.3 (2H, t, J 7 Hz), 2.5 (3H, s), 1.8 (2H, qn, J 5 Hz)

m/e = 426

$\text{C}_{20}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_3\text{S}$  requires 426

15

**Example 8**

**5-Methylthio-6-trifluoromethyl-1-[3-[(2-dimethylaminoethyl)carbamoyl] phenyl carbamoyl]indoline.**

20 To a suspension of 5-methylthio-6-trifluoromethyl-1-(3-carboxy phenyl carbamoyl) indoline (0.5g, 1.26mmol) in dichloromethane (20ml) was added oxalyl chloride (0.3ml, 2.52 mmol) and dimethylformamide (3 drops). After effervescing had subsided the reaction mixture was evaporated to dryness under reduced pressure. It was then dissolved in tetrahydrofuran (30ml) and added to a solution of N,N-dimethylethylenediamine (0.405g, 6.33mmol) and triethylamine (0.2ml, 1.4mmol) in tetrahydrofuran at 0 °C. After 2 hours the reaction mixture was basified with 5M NaOH and water was added forming a white precipitate. This was filtered and dried to give the product a white solid (0.25g, 45%), m.p. 91-93° C.

25 30  $^1\text{H}$  NMR(DMSO) $\delta$  8.8(1H,s); 8.35(1H,t,J5Hz); 8.2(1H,s); 8.0(1H,s); 7.75(1H,d,J7Hz); 7.5(3H,m); 7.4(1H,t,J7Hz); 4.2(2H,t,J7Hz); 3.3(4H,t,J7Hz); 2.5(3H,s); 2.4(2H,t,J7Hz); 2.2(6H,s).

m/e = 466

$\text{C}_{22}\text{H}_{25}\text{F}_3\text{N}_4\text{O}_2\text{S}$  requires 466

35

**Example 9**

**5-Methylthio-6-trifluoromethyl-1-[4-[(2-dimethylaminoethyl)carbamoyl] phenyl carbamoyl]indoline.**

5 This was made in the same manner as 5-methylthio-6-trifluoromethyl-1-[3-(2-dimethylaminoethyl)carbamoyl phenyl carbamoyl]indoline to give the product as a white solid (0.22g, 37%, m.p. 154-5°C.

<sup>1</sup>H NMR(DMSO)δ = 8.85(1H,s); 8.25(1H,t,J5Hz); 8.2(1H,s); 7.8(2H,d,J7Hz);  
 10 7.7(2H,d,J7Hz); 7.5(1H,s); 4.2(2H,t,J7Hz); 3.3(4H,t,J7Hz); 2.5(3H,s);  
 2.4(2H,t,J7Hz); 2.2(6H,s).  
 m/e = 466  
 $C_{22}H_{25}F_3N_4O_2S$  requires 466

15 **Example 10**

**5-Methylthio-6-trifluoromethyl-1-(3-ethoxycarbonyl phenyl carbamoyl)indoline**

To a stirred solution of carbonyl diimidazole (1.782g, 11 mmol) in dichloromethane (20 ml) was added dropwise a solution of ethyl 3-amino benzoate (1.65g, 10 mmol) in dichloromethane (20 ml). After 1 hour the reaction mixture was evaporated under reduced pressure before being treated with 5-methylthio-6-trifluoromethyl indoline (2.33g, 10 mmol) and dimethylformamide (30 ml) and heated to 100°C. After 1 hour the reaction mixture was cooled and water added forming a yellow precipitate. This was filtered and dried to give the product as a yellow solid (4.19g, 99%), m.p.  
 25 195-7°C.

<sup>1</sup>H NMR (DMSO) δ: 8.85 (1H, s); 8.2 (2H, d, J6Hz); 7.9 (1H, d, J7Hz); 7.6 (1H, d, J7Hz); 7.4 (2H, t, J6Hz); 4.3 (2H, q, J7Hz); 4.2 (2H, t, J8Hz); 3.25 (2H, t, J8Hz); 2.5 (3H, s); 1.3 (3H, t, J7Hz).

30

**Example 11**

**5-Methylthio-6-trifluoromethyl-1-(4-ethoxycarbonyl phenyl carbamoyl) indoline**

This was made in the same manner as 5-methylthio-6-trifluoromethyl-1-(3-ethoxycarbonyl phenyl carbamoyl) indoline using ethyl-4-amino benzoate to give the product as a yellow solid (3.948g, 93%), m.p. > 200°C.

<sup>1</sup>H NMR (DMSO) δ: 8.95 (1H, s); 8.2 (1H, s); 7.9 (2H, d, J7Hz); 7.75 (2H, d, J7Hz); 7.4 (1H, s), 4.2 (4H, m); 3.25 (2H, t, J8Hz); 2.5 (3H, s); 1.3 (3H, t, J7Hz)

**Example 12**

**5-Methylthio-6-trifluoromethyl-1-(3-carboxy phenyl carbamoyl)indoline**

To a suspension of 5-methylthio-6-trifluoromethyl-1-(3-ethoxy carbonyl phenyl carbamoyl) indoline (3g, 7.1 mmol) in ethanol (30 ml) was added aqueous sodium hydroxide solution (5M) (7.1 ml, 35.5 mmol) and heated gently for 2 hours. It was 10 then allowed to cool and acidified with aqueous hydrochloric acid (5M) forming a white precipitate which was filtered and dried to yield the product as a white solid (2.324g, 83%), mp >200° C.

<sup>1</sup>H NMR (DMSO) δ: 12.95 (1H, s); 8.85 (1H, s); 8.2 (2H, s); 7.85 (1H, d, J7Hz); 7.6 (1H, d, J7Hz); 7.4 (2H, t, J7Hz); 4.2 (2H, t, J6Hz); 3.25 (2H, t, J6Hz); 2.5 (3H, s)

**Example 13**

**5-Methylthio-6-trifluoromethyl-1-(4-carboxy phenyl carbamoyl) indoline**

20 This was made in the same manner as 5-methylthio-6-trifluoromethyl-1-(3-carboxy phenyl carbamoyl)indoline using 5-methylthio-6-trifluoromethyl-1-(4-ethoxycarbonyl phenyl carbamoyl) indoline to give the product as a pale green solid (2.455g, 88%), mp >200° C.

25 <sup>1</sup>H NMR (DMSO) δ: 1.27 (1H, s); 8.9 (1H, s); 8.2 (1H, s); 7.9 (2H, d, J7Hz); 7.7 (2H, d, J7Hz); 7.4 (1H, s); 4.2 (2H, t, J8Hz); 3.75 (2H, t, J8Hz); 2.5 (3H, s)

**Example 14**

30 **5-Methylthio-6-trifluoromethyl-1-[3-(2-methoxy) ethoxy phenyl carbamoyl] indoline**

Prepared by the analogous routes as Example 1 (36%), m.p. 171-172.7°C

**Example 15**

35 **5-Methylthio-6-trifluoromethyl-1-(3-ethoxyphenyl carbamoyl) indoline**

Prepared by the reaction of 3-ethoxyphenyl isocyanate with 5-thiomethyl-6-trifluoromethyl indoline (22%), m.p. 233-4°C

**Example 16**

**5-Methylthio-6-trifluoromethyl-1-[3-(2-hydroxyethyl) amidophenyl carbamoyl] indoline**

5

Prepared by an analogous route to Example 8 (52%), m.p. 215-215°C.

**Example 17**

**1-(3-(Dimethylaminomethyl)phenylcarbamoyl)-5-methylthio-6-**

10 **trifluoromethylindoline**

A stirred solution of 1,1' Carbonyldiimidazole (0.65g, 4.0 mmol) in dichloromethane (DCM) (60 ml) was treated with 3-N,N-Dimethylaminomethyl aniline (D25) (0.55g, 3.6 mmol). The reaction mixture was stirred at room temperature for 0.5 hour, 15 evaporated *in vacuo*, and then treated with 5-thiomethyl-6-trifluoromethyl indoline (D7) (0.85g, 3.6 mmol) in N,N-dimethylformamide (15 ml). The reaction mixture was stirred at room temperature for 24 hours, after which it was slowly added to water (150 ml) and left to stand for 0.5 hour. It was then extracted with ethyl acetate (2 x 100 ml), followed by DCM (2x 100 ml). The combined organic extracts were 20 dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated *in vacuo* to afford a brown oil (1.93g). This was chromatographed on silica gel eluting with 0 to 10% methanol/DCM affording the title compound as a white powder (0.16g, 11%).

<sup>1</sup>H NMR (200MHz, d<sup>6</sup>DMSO)

25

δ(ppm): 8.12 (s, 1H), 8.21 (s, 1H), 7.50 (m, 3H), 7.23 (t, 1H), 6.95 (d, 1H), 4.20 (t, 2H), 3.40 (s, 2H), 3.29 (t, 2H), 2.50 (s, 3H), 2.17 (s, 6H)

**Example 18**

30 **1-[3-[(2-Aminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-**  
**trifluoromethyl indoline (E18)**

The acid chloride was formed using the carboxylic acid from Example 12 (1.2g, 3.1 mmol) and oxalyl chloride (0.72ml, 8.1 mmol) in the usual way, dissolved in THF, 35 and added to a solution of tert-butyl N-(2-aminoethyl)-carbamate (0.5g, 3.1 mmol) in THF to give the Boc-protected ethylene diamine (1.6g, 100%). A portion of this (0.7g, 1.3 mmol) in EtOAc was deprotected by bubbling HCl gas through the solution

for 5 mins. Filtration afforded the title compound as a tan powder (0.44g, 67%).  
M.pt. 175°C (dec).

5 NMR 250 MHz, d<sup>6</sup>-DMSO δ: 8.90 (s, 1H), 8.71 (t, 1H), 8.21 (s, 1H), 8.10 (br, 3H),  
7.75 (d, 1H), 7.62 (d, 1H), 7.45 (s, 1H), 7.40 (t, 1H), 4.25 (t, 2H), 3.54 (t, 2H), 3.25  
(t, 1H), 2.98 (t, 2H), 2.50 (s, 3H).

m/e 438, C<sub>20</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S requires 438.

10 Example 19

1-[3-[2-Diethylaminocethyl]carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline (E19)

15 This was prepared in 8% yield by the same methodology as for Example 8, affording  
the product as a white solid. m.p. 76-8°C.

NMR (D6-DMSO): 1.00 (6H, t), 2.40-2.60 (6H, m), 2.50 (3H, s), 3.30 (4H, m), 4.20  
(2H, t), 7.40 (1H, t), 7.50 (2H, m), 7.75 (1H, m), 8.05 (1H, s), 8.25 (1H, s), 8.35 (1H,  
t), 8.85 (1H, s).

20

Example 20

1-[3-[(2-Diisopropylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline (E20)

25 This was prepared in 70% yield by the same method as for Example 8, affording the  
title compound as a white solid. m.p. 97-99°C.

30 NMR (D6-DMSO): 1.00 (12H, d), 2.50 (3H, s), 2.95 (2H, quintuplet), 3.30 (4H, m),  
4.20 (2H, t), 7.35 (1H, t), 7.45 (2H, m), 7.75 (1H, d), 8.05 (1H, s), 8.25 (1H, s), 8.30  
(1H, t), 8.80 (1H, s).

Example 21

1-[3-[(2-Dibutylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-  
trifluoromethyl indoline (E21)

35

This was prepared in 53% yield by the same method as for Example 8, affording the  
title compound as a white solid. m.p. 128-130°C.

NMR (D6-DMSO): 0.90 (6H, t), 1.20-1.40 (8H, m), 2.40 (4H, t), 2.50 (3H, s), 2.55 (2H, t), 3.30 (4H, m), 4.20 (2H, t), 7.35 (1H, t), 7.45 (2H, m), 7.75 (1H, d), 8.05 (1H, s), 8.25 (2H, m), 8.80 (1H, s).

5    **Example 22**

1-[3-[(2-Dimethylaminoethyl)methylcarbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E22)

10    The carboxylic acid from Example 12 (0.5g, 1.25 mmol) in dichloromethane (10 ml) was treated with oxalyl chloride (0.3ml, 3.4 mol) and DMF (catalytic). Solution was stirred for 1h and evaporated to dryness. The residue in dry THF (5 ml) was added to a stirred solution of triethylamine (0.3 ml, 4 mmol) and N,N,N'-trimethylethylenediamine (0.5 ml, 4.5 mmol) in dry THF (10 ml). Following 3 hours at room temperature, the solution was partitioned (H<sub>2</sub>O/EtOAc). Drying and removal  
15    of the organic layers followed by recrystallisation (EtOAc/60°-80° petrol) afforded the title compound (0.5g, 83%) as a white solid. M.pt. 140°-141°C.

20    NMR 250 MHz, CDCl<sub>3</sub>, δ: 8.30 (s, 1H), 7.47 (br, 2H), 7.30 (m, 1H), 7.10 (d, 1H), 6.86 (s, 1H), 4.15 (t, 2H), 3.65 (br, 1H), 3.30 (t, 2H), 3.05 (br d, 2H), 2.58 (br, 1H), 2.50 (s, 3H), 2.31 (s, 3H), 2.11 (s, 3H), 1.70 (s, 3H).

Mass spec.

Example 23

25    1-[3-[(2-Dimethylaminopropyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E23)

This was prepared using the same methodology as for Example 8, affording the product as a white solid m.p. 86-8°C.

30

NMR (D6-DMSO): 1.65 (2H, quintuplet), 2.10 (6H, s), 2.25 (2H, t), 2.50 (3H, s), 3.30 (4H, m), 4.20 (2H, t), 7.35 (1H, t), 7.45 (2H, m), 7.75 (1H, d), 8.05 (1H, s), 8.25 (1H, s), 8.55 (1H, t), 8.85 (1H, s).

**Example 24****1-[3-[(2-Pyridylmethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E24)**

5 This was prepared by the same method as for Example 8 affording the title compound in 54% yield as a white solid m.p. 116-8°C.

NMR (D6-DMSO): 2.50 (3H, s), 3.30 (2H, t), 4.20 (2H, t), 4.60 (2H, d), 7.20-7.40 (2H, m), 7.40-7.50 (2H, m), 7.60 (1H, d), 7.75 (2H, m), 8.05 (1H, s), 8.20 (1H, s),  
10 8.50 (1H, d), 8.85 (1H, s), 9.10 (1H, t).

**Example 25****1-[3-[(3-Dimethylamino-2-propyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E25)**

15 This was prepared by a similar method to Example 8 affording the title compound in 66% yield as a white solid m.p. 86-88°C.

NMR (D6-DMSO): 1.10 (3H, d), 2.15 (6H, s), 2.30-2.50 (2H, m), 2.50 (3H, s), 3.30 (2H, t), 4.20 (3H, m), 7.40 (1H, t), 7.45 (2H, m), 7.75 (1H, d), 8.00 (1H, s), 8.15 (1H, d), 8.20 (1H, s), 8.80 (1H, s)

**Example 26****1-[3-[(2-(N-Methyl-N-phenyl)ethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E26)**

This was prepared by similar methodology to Example 8 affording the title compound in 17% yield as a white solid, m.p. 88-90°C.

30 NMR (D6-DMSO): 2.50 (3H, s), 2.95 (3H, s), 3.30 (2H, t), 3.50 (4H, m), 4.20 (2H, t), 6.60 (1H, t), 6.85 (2H, d), 7.15 (2H, m), 7.35 (1H, t), 7.45 (2H, m), 7.75 (1H, d), 8.05 (1H, s), 8.20 (1H, s), 8.55 (1H, t), 8.80 (1H, s)

**Example 27****1-[3-(4-Dimethylamino-1-oxobutyl)phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E27)**

5    3-N,N-Dimethylaminopropylcarbonyl aniline\* (0.81g, 3.9 mmol) was reacted with phenyl chloroformate (0.54 ml, 4.3 mmol) and triethylamine (0.6 ml, 4.3 mmol) to form the carbamate. This was added to a solution of 5-methylthio-6-trifluoromethyl indoline (D22) (0.5g of hydrochloride salt, 1.8 mmol) and triethylamine (0.25 ml, 1.8 mmol) in DMF (10 ml). The solution was heated to 120°C for 24 hours and the  
 10    evaporated to dryness. This residue was partitioned (EtOAc/H<sub>2</sub>O). Organics were dried and removed *in vacuo*, the residue flash chromatographed (dichloromethane - 20% MeOH/DCM) to afford the title compound (60 mg, 7%) as a yellow powder, M.pt. 178°-180°C.

15    NMR CDCl<sub>3</sub>, 250 MHz δ: 8.32 (s, 1H), 8.07 (s, 1H), 7.93 (d, 1H), 7.62 (d, 1H), 7.38 (t, 1H), 7.25 (s, 1H), 4.25 (t, 2H), 3.30 (t, 2H), 3.12 (t, 2H), 2.82 (t, 2H), 2.60 (s, 6H), 2.50 (s, 3H), 2.10 (t, 2H).  
 Mass spec m/z=466 (M<sup>+</sup>H)  
 \*Prepared using methodology of Yamguchi, S and Kuninobu K, *Bull. Chem. Soc. JPN.* 50 (11), 3033-38, 1977.

**Example 28****1-[3-(N-methylpiperazinylcarbonyl)phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E28)**

25    The carboxylic acid from Example 12 (0.5g, 1.25 mmol) in dichloromethane (10 ml) was treated with oxalyl chloride (0.3 ml, 3.4 mmol) and DMF (catalytic). The solution was stirred for 1 hour and evaporated to dryness. The residue in dry THF (5 ml) was added to a solution of triethylamine in dry (0.3 ml, 4 mmol) and N-Methyl  
 30    piperazine (0.5 ml, 4.5 mmol) in THF (10 ml). After 3 hours of stirring the solution was partitioned (EtOAc/H<sub>2</sub>O). Removal and drying of the solvent followed by rext (EtOAc/60°-80°C petrol) afforded the title compound as a white powder, m.pt. 220°-222°C.

35    NMR 250 MHz, CDCl<sub>3</sub>, δ: 8.30 (s, 1H), 7.50 (d, 1H), 7.38 (s, 1H), 7.30 (m, 2H), 7.05 (m, 2H), 4.15 (t, 2H), 3.80 (br, 2H), 3.48 (br, 2H), 3.29 (t, 2H), 2.47 (s, 3H), 2.32 (br, 7H).

**Example 29****1-[3-[(2-Piperid-1-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E29)**

5 This was prepared by a similar method to Example 8, affording the title compound in 46% yield as a white solid, m.p. 79-81°C.

NMR (D6-DMSO): 1.50 (6H, m), 2.35 (4H, m), 2.45 (2H, t), 3.30 (2H, t), 3.40 (2H, t), 4.20 (2H, t), 7.35 (1H, t), 7.45 (1H, s), 7.75 (1H, d), 8.00 (1H, s), 8.20 (1H, s),  
10 8.30 (1H, t), 8.80 (1H, s).

**Example 30****1-[3[(2-Morpholin-4-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E30)**

15 This was prepared by similar methodology to Example 8, affording the title compound in 50% yield as a white solid, m.p. 198-200°C.

NMR (D6-DMSO): 2.45 (6H, m), 2.50 (3H, s), 3.30 (2H, t), 3.40 (2H, t), 3.55 (4H, m), 4.20 (2H, t), 7.35 (1H, t), 7.45 (2H, m), 7.75 (1H, d), 8.05 (1H, s), 8.20 (1H, s),  
20 8.35 (1H, t), 8.80 (1H, s).

**Example 31****1-[3-[(N-Ethylpyrrolidin-2-ylmethyl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline (E31)**

The carboxylic acid from Example 12 (0.5g, 1.25 mol) in dichloromethane (10 ml) was treated with oxalyl chloride (6.3 ml, 3.4 mmol) and DMF (catalytic). The solution was stirred for 1 hour and evaporated to dryness. The residue in dry THF (5 ml) was added to a stirred solution of triethylamine (0.3 ml, 4 mmol) and N-Ethyl-2-aminomethyl pyrrolidine (0.57 g, 4.5 mmol). After 3 hours at room temperature the solution was partitioned (EtOAc/H<sub>2</sub>O). Drying and removal of organics followed by rexst (EtOAc/60°-80°C petrol) afforded the title compound as a white powder, m.pt. 174°-175°C.

35 NMR 250 MHz CDCl<sub>3</sub>, δ: 8.34 (s, 1H), 7.78 (m, 2H), 7.38 (m, 2H), 7.25 (s, 1H), 6.96 (br, 1H), 6.82 (s, 1H), 4.16 (m, 2H), 3.70 (m, 1H), 3.30 (m, 4H), 2.50 (s, 3H), 2.23 (m, 2H), 1.90 (m, 2H), 1.70 (m, 4H), 1.15 (t, 3H).

Mass spec m/z = 506 (M<sup>+</sup>)

**Example 32**

5 **1-[3-[(2-Pyrrolidin-1-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E32)**

This was prepared by similar methodology to Example 8, affording the title compound in 60% yield as a white solid, m.p. 91-93°C.

10 NMR (D6-DMSO): 1.65 (4H, m), 2.45 (4H, m), 2.50 (3H, s), 2.55 (2H, t), 3.20 (2H, t), 3.30 (2H, t), 4.20 (2H, t), 7.35 (1H, t), 7.45 (2H, m), 7.75 (1H, d), 8.05 (1H, s), 8.25 (1H, s), 8.40 (1H, t), 8.85 (1H, s).

**Example 33**

15 **1-[3-[(N-Benzylpyrrolidin-3-yl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E33)**

The carboxylic acid from Example 12 (0.5g, 1.25 mmol) in dichloromethane (10 ml) was treated with oxalyl chloride (0.3 ml, 3.4 mmol) and DMF (catalytic). The

20 solution was stirred for 1 hour and evaporated to dryness. The residue in dry THF (3 ml) was added to a stirred solution of triethylamine (0.3ml, 4 mmol) and 3-amino-N-benzyl pyrrolidine (0.79g, 4.5 mmol) in dry THF (10 ml). Following 3 hours at room temperature the solution was partitioned (H<sub>2</sub>O/EtOAc). Drying and removal of solvent followed by rext (EtOAc/60°-80°C petrol) afforded the title compound  
25 (0.62g, 89%) as a white powder. M.pt. 174°-175°C.

NMR 250 MHz, CDCl<sub>3</sub>, δ: 8.30 (s, 1H), 7.70 (m, 2H), 7.45-7.18 (m, 6H), 4.12 (br, 1H), 4.11 (m, 2H), 3.60 (s, 2H), 3.26 (t, 2H), 2.93 (m, 1H), 2.68 (m, 2H), 2.48 (s, 3H), 2.31 (m, 2H), 1.72 (m, 1H).

30 Mass spec: m/z=554 (M<sup>+</sup>)

**Example 34**

1-3-[(2-Dimethylaminomethyl)pyrrolidin-1-yl]carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline (E34)

35

This was prepared using similar methodology to Example 8, affording the title compound in 31% yield as a white solid, m.p. 105-7°C.

NMR (D6-DMSO): 1.80-2.00 (4H, m), 2.10 (6H, s), 2.20 (2H, m), 2.50 (3H, s), 3.25 (2H, t), 3.40 (2H, m), 4.20 (3H, m), 7.05 (1H, d), 7.30 (1H, t), 7.45 (1H, s), 7.60 (2H, m), 8.20 (1H, s), 8.55 (1H, bs).

5      **Example 35**

**1-[3-[(3-Dimethylaminopyrrolidin-1-yl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline (E35)**

10     This was prepared using similar methodology as Example 8, affording the title compound in 43% yield as a white solid, m.p. 114-6°C.

NMR (D6-DMSO): 1.70 (1H, m), 2.05 (1H, m), 2.10 (3H, s), 2.15 (3H, s), 2.50 (3H, s), 2.60 (1H, m), 3.15-3.75 (6H, m), 4.20 (2H, t), 7.15 (1H, m), 7.35 (1H, t), 7.45 (1H, s), 7.65 (1H, m), 7.75 (1H, m), 8.20 (1H, s), 8.75 (1H, s).

15

**Example 36**

**1-[2-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E36)**

20

This was prepared using similar methodology to Example 17, affording the title compound in 70% yield as a white solid m.p. >200°C.

25

NMR (CDCl<sub>3</sub>): 2.25 (6H, s), 3.20 (2H, t), 3.50 (2H, s), 3.85 (3H, s), 4.05 (2H, t), 6.85 (1H, s), 6.95 (1H, t), 7.05 (1H, d), 7.25 (1H, s), 7.30 (1H, d), 8.15 (1H, d), 8.30 (1H, s).

30

**Example 37**

**1-[2-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E37)**

This was prepared from the aniline D33 and 5-methoxy-6-trifluoromethyl indoline (D29) using the procedure of Example 1 affording the title compound in 19% yield as a pink crystalline solid. m.p. 166-168°C.

35

NMR (CDCl<sub>3</sub>): 2.25 (6H, s), 2.60 (2H, m), 3.25 (2H, t), 3.85 (3H, s), 4.05 (2H, t), 6.85 (1H, s), 6.95-7.10 (2H, m), 7.15-7.30 (2H, m), 7.70 (1H, d), 8.20 (1H, s).

**Example 38****1-[3-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E38)**

5 This was prepared using similar methodology to Example 37, affording the title compound in 2% yield as a white solid m.p. 167-169°C.

NMR (CDCl<sub>3</sub>): 2.30 (6H, s), 2.55 (2H, m), 2.80 (2H, m), 3.30 (2H, t), 4.15 (2H, t), 6.85 (1H, s), 6.95 (1H, m), 7.10-7.30 (4H, m), 8.25 (1H, s).

10

**Example 39****1-[3-(3-(Dimethylamino)propyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E39)**

15 This was prepared using similar methodology to Example 37 affording the title compound in 27% yield as a white crystalline solid, m.p. 121-3°C.

NMR (CDCl<sub>3</sub>): 1.70 (2H, m), 2.30 (6H, s), 2.40 (2H, t), 2.55 (2H, t), 3.20 (2H, t), 3.85 (3H, s), 4.05 (2H, t), 6.75 (1H, s), 6.85 (1H, d), 7.20 (2H, m), 7.40 (2H, m), 8.25

20 (1H, s).

**Example 40****1-[3-[(2-Dimethylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E40)**

25

1-(3-Carboxyphenylcarbamoyl)-5-methoxy-6-trifluoromethyl indoline, which was prepared in analogous manner to Example 12 (0.31g, 0.8 mmol) was dissolved in dichloromethane (10 ml) and treated with oxalyl chloride (0.19ml, 2.2 mmol) and DMF (catalytic). The solution was stirred for 1 hour and evaporated to dryness. The

30 residue in dry THF (5 ml) was added to a stirred solution of triethylamine (0.35 ml, 2.56 mmol) and N,N-dimethylethylenediamine (0.31 mmol, 2.88 mmol) in dry THF.

After 3 hours stirring, the solution was partitioned (EtOAc/H<sub>2</sub>O). Drying and removal of the solvent followed by recst of (EtOAc/PE 60°-80°) afforded the title compound as a white powder. M.pt. 159°-160°C.

35 Mass spec/ m/z=451 (M<sup>+</sup>H)

**Example 41**

**1-[4-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E41)**

5 This was prepared in 59% yield using similar methodology to Example 36, affording the title compound as a white solid, m.p. 169-70°C.

NMR (CDCl<sub>3</sub>): 2.10 (6H, s), 3.25 (2H, t), 3.30 (2H, s), 3.80 (3H, s), 4.15 (2H, t), 7.20 (3H, m), 7.50 (2H, d), 8.10 (1H, s), 8.50 (1H, s).

10

**Example 42**

**1-[4-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E42)**

15 This was prepared by the same method as for Example 37, affording the title compound in 6% yield as a white solid m.p. 181-184°C.

NMR (D6-DMSO): 2.15 (6H, s), 2.40 (2H, t), 2.65 (2H, t), 3.25 (2H, t), 3.80 (3H, s), 4.20 (2H, t), 7.10 (2H, d), 7.20 (1H, s), 7.45 (2H, d), 8.10 (1H, s), 8.50 (1H, s)

20

**Example 43**

**1-[3-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E43)**

25 This was prepared by similar methodology to Example 36 affording the title compound in 19% yield as a white crystalline solid m.p. 134-40°C.

NMR (CDCl<sub>3</sub>): 2.50 (6H, s), 3.25 (2H, t), 3.75 (2H, s), 3.85 (3H, s), 4.15 (2H, t), 6.85 (1H, s), 6.95 (1H, s), 7.05 (1H, d), 7.30 (1H, d), 7.65 (2H, m), 8.25 (1H, s).

30

**Example 44**

**1-[3-(3-(Dimethylamino)propyloxy)phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E44)**

35 This was prepared using similar methodology to Example 8, affording the title compound in 14% yield as a white solid. m.p. 149-151°C.

NMR (D6-DMSO): 1.85 (2H, quintuplet), 2.15 (6H, s), 2.35 (2H, t), 2.50 (3H, s), 3.24 (2H, t), 3.95 (2H, t), 4.20 (2H, t), 6.60 (1H, m), 7.15 (1H, s), 7.15-7.25 (2H, m), 7.55 (1H, s), 8.20 (1H, s), 8.55 (1H, s).

5   **Example 45**

**1-[3-[(2-(Dimethylamino)ethoxy)iminomethyl]phenylcarbamoyl-5-methylthio-6-trifluoromethyl indoline (E45)**

This was prepared from aniline D32 using the same methodology as for Example 27  
10   affording the title compound in 64% yield as a white solid m.p. >250°C.

NMR (D6-DMSO): 2.10 (6H, s), 2.50 (3H, s), 3.30 (6H, m), 4.20 (2H, t), 7.25 (1H, d), 7.35 (1H, t), 7.65 (1H, d), 7.85 (1H, s), 8.25 (2H, s), 8.80 (1H, s).

15   **Example 46**

**1-[Phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline (E46)**

This was prepared from phenyl isocyanate and 5-methylthio-6-trifluoromethyl indoline in 34% yield m.p. 163-165°C.

20

NMR (CDCl<sub>3</sub>): 2.50 (3H, s), 3.30 (2H, t), 4.15 (2H, t), 6.40 (1H, bs), 7.10 (1H, t), 7.25 (1H, s), 7.35 (1H, t), 7.40-7.50 (3H, m), 8.35 (1H, s).

**Example 47**

**25   1-(4-Hydroxymethylphenylcarbamoyl)-5-methylthio-6-trifluoromethyl indoline**

4-Aminobenzyl alcohol was converted to the phenyl carbamate and treated with 5-methoxy-6-trifluoromethyl indoline as in the method of Example 27.

Chromatography using ethyl acetate as eluant gave the title compound as a white  
30   crystalline solid. m.p. 184-7°C.

<sup>1</sup>H NMR (250 MHz; DMSO) δ: 3.28 (2H, t, J 8Hz), 3.37 (3H, s), 4.19 (2H, t, J 8Hz), 4.45 (2H, br s), 5.11 (1H, br), 7.23 (2H, d, J 7Hz), 7.46 (1H, s), 7.51 (1H, d, J 7Hz), 8.22 (1H, s), 8.62 (1H, s)

35

**Example 48****1-[(5-Bromo-2-thienyl)carbamoyl]-5-methoxy-6-trifluoromethyl indoline (E48)**

5 This was prepared from 5-bromo-thiophene-2-carboxylic acid in 78% via acyl azide formation and Curtius rearrangement to form the isocyanate and then treatment with 5-methoxy-6-trifluoromethyl indoline (D29).

NMR (D6-DMSO): 3.30 (2H, t), 3.85 (3H, s), 4.10 (2H, t), 6.55 (1H, d), 6.95 (1H, d), 7.20 (1H, s), 8.10 (1H, s), 10.10 (1H, s).

10

**Example 49****1-[2-Thienylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline (E48)**

15 A mixture of 5-methoxy-6-trifluoromethyl-1-(5-bromo-2-thienyl) carbamoyl indoline (E48) (0.64g, 1.5 mmol), sodium carbonate (1.1g), pyridine-3-boronic acid (0.55g, 4.5 mmol) and tetrakis triphenylphosphine palladium(0) (0.1g) in dimethoxyethane/water (20 ml/5 ml) was heated to reflux overnight under argon. Extraction workup and chromatography afforded the title compound in 27% yield as a white solid, m.p. 240-244°C.

20

NMR (D6-DMSO): 3.30 (2H, t), 3.85 (3H, s), 4.15 (2H, t), 6.75 (1H, m), 6.85 (1H, m), 6.90 (1H, m), 7.20 (1H, s), 8.15 (1H, s), 9.80 (1H, s).

**Pharmacological data****[<sup>3</sup>H]-mesulergine binding to rat or human 5-HT<sub>2C</sub> clones expressed in 293 cells  
in vitro**

5

Compounds were tested following the procedure outlined in WO 94/04533. The compounds of examples 1 to 49 have pKi values of 6.0 to 9.2.


**Reversal of MCPP-induced Hypolocomotion**

10 Compounds were tested following the procedure outlined in WO 94/04533. The compound of example 8 has an ID<sub>50</sub> of 10.0 mg/kg p.o.

## Claims:

1. A compound of formula (I) or a salt thereof:

5



wherein:

10 P represents phenyl, a quinoline or isoquinoline residue, or a 5-membered or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;

R is hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, NR<sup>4</sup>COR<sup>5</sup>, C<sub>1-6</sub> alkylthio, cyano, nitro, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, NR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup>, CHO, COR<sup>6</sup>,

15 CH<sub>2</sub>OR<sup>6</sup>, CO<sub>2</sub>R<sup>6</sup>, OR<sup>6</sup> or S(O)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup>, where n is 1 or 2 and R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, aryl or arylC<sub>1-6</sub>alkyl;


R<sup>1</sup> is hydrogen, X(CR<sup>8</sup>R<sup>9</sup>)<sub>p</sub>R<sup>10</sup> where X is a bond, oxygen, sulphur, C=O, CH=N-O, CONR<sup>7</sup> or NR<sup>7</sup> where R<sup>7</sup> is hydrogen or C<sub>1-6</sub> alkyl; R<sup>8</sup> and R<sup>9</sup> are independently hydrogen or C<sub>1-6</sub> alkyl; p is 0 to 6 and R<sup>10</sup> is hydroxy, C<sub>1-6</sub>alkoxy,

20 NR<sup>4</sup>R<sup>5</sup> where R<sup>4</sup> and R<sup>5</sup> are as defined above for R, or R<sup>4</sup> and R<sup>5</sup> together form a C<sub>2</sub>-C<sub>6</sub> methylene chain optionally containing an O, S or NR<sup>7</sup> group and optionally substituted by NR<sup>4</sup>R<sup>5</sup> or C<sub>1-6</sub> alkylNR<sup>4</sup>R<sup>5</sup> where R<sup>4</sup> and R<sup>5</sup> are independently C<sub>1-6</sub> alkyl, or one of R<sup>4</sup> and R<sup>5</sup> represents an optionally substituted alicyclic amine attached directly or via a C<sub>1-6</sub> alkyl group, or R<sup>10</sup> is CO<sub>2</sub>R<sup>11</sup> where R<sup>11</sup> is

25 hydrogen, C<sub>1-6</sub> alkyl or aryl;

R<sup>2</sup> is hydrogen or C<sub>1-6</sub> alkyl;

R<sup>3</sup> is a group of formula (i):




30

in which:

X and Y are both nitrogen, one is nitrogen and the other is carbon or a CR<sup>12</sup> group or one is a CR<sup>12</sup> group and the other is carbon or a CR<sup>12</sup> group;

$R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  groups are independently hydrogen,  $C_{1-6}$  alkyl optionally substituted by one or more halogen atoms,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl,  $C_{3-6}$  cycloalkyl $C_{1-6}$ alkoxy,  $C_{2-6}$  alkynyl,  $C_{3-6}$  cycloalkyloxy,  $C_{3-6}$  cycloalkyl- $C_{1-6}$  alkyl,  $C_{1-6}$  alkylthio,  $C_{3-6}$  cycloalkylthio,  $C_{3-6}$  cycloalkyl-  
5  $C_{1-6}$  alkylthio,  $C_{1-6}$  alkoxy, hydroxy, halogen, nitro,  $CF_3$ ,  $C_2F_5$ ,  $OCF_3$ ,  $SCF_3$ ,  $SO_2CF_3$ ,  $SO_2F$ , formyl,  $C_{2-6}$  alkanoyl, cyano, optionally substituted phenyl or thienyl,  $NR^4R^5$ ,  $CONR^4R^5$  or  $CO_2R^6$  where  $R^4$ ,  $R^5$  and  $R^6$  are as defined for  $R^1$ ; or  $R^{14}$  and  $R^{15}$  form part of an optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring;


10  $R^{16}$  and  $R^{17}$  are independently hydrogen or  $C_{1-6}$  alkyl; or  $R^3$  is a group of formula (ii):



15 (ii)

in which X and Y are both nitrogen, one is nitrogen and the other is a  $CR^{12}$  group or X and Y are both  $CR^{12}$  groups,  $R^{18}$  is hydrogen or  $C_{1-6}$  alkyl, and  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are as defined in formula (I); or

20  $R^3$  is a group of formula (iii):



(iii)

25 in which  $R^{14}$ ,  $R^{15}$ , X and Y are as defined in formula (i) and Z is O, S,  $CH_2$  or  $NR^{19}$  where  $R^{19}$  is hydrogen or  $C_{1-6}$  alkyl.

2. A compound according to claim 1 in which  $R^1$  is  $CO_2R^{11}$  where  $R^{11}$  is hydrogen or  $C_{1-6}$  alkyl, or  $R^1$  is  $X(CH_2)_pR^{10}$  where X is a bond, CONH or oxygen, p is 1 to 3, and  $R^{10}$  is OH or  $NR^4R^5$  where  $R^4$  and  $R^5$  are  $C_{1-6}$  alkyl.

30 3. A compound according to claim 1 or 2 in which  $R^2$  is hydrogen.

4. A compound according to any one of claims 1 to 3 in which  $R^3$  is a group of formula (i).

5. A compound according to any one of claims 1 to 4 in which P is phenyl.

6. A compound according to claim 1 which is:

5-Methoxy-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

5-Methoxy-6-trifluoromethyl-1-[4-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-[3-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

5-Methoxy-6-trifluoromethyl-1-[2-(2-dimethylamino)-ethoxyphenyl-carbamoyl]indoline,

10 5-Methylthio-6-trifluoromethyl-1-[3-(2-hydroxy)-ethoxyphenyl-carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-[3-ethoxycarbonylmethoxy) phenyl carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-[3-(3-hydroxypropyloxy)-phenyl-carbamoyl]indoline,

15 5-Methylthio-6-trifluoromethyl-1-[3-(2-dimethylaminoethyl)carbamoyl phenyl carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-[4-(2-dimethylaminoethyl)carbamoyl phenyl carbamoyl]indoline,

5-Methylthio-6-trifluoromethyl-1-(3-ethoxycarbonyl phenyl carbamoyl)indoline,

20 5-Methylthio-6-trifluoromethyl-1-(4-ethoxycarbonyl phenyl carbamoyl) indoline,

5-Methylthio-6-trifluoromethyl-1-(3-carboxy phenyl carbamoyl)indoline,

5-Methylthio-6-trifluoromethyl-1-(4-carboxy phenyl carbamoyl) indoline,

5-Methylthio-6-trifluoromethyl-1-[3-(2-methoxy) ethoxy phenyl carbamoyl] indoline,

5-Methylthio-6-trifluoromethyl-1-(3-ethoxyphenyl carbamoyl) indoline,

25 5-Methylthio-6-trifluoromethyl-1-[3-(2-hydroxyethyl) amidophenyl carbamoyl] indoline,

1-(3-(Dimethylaminomethyl)phenylcarbamoyl)-5-methylthio-6-trifluoromethylindoline,

1-[3-[(2-Aminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl

30 indoline,

1-[3-[2-Diethylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-Diisopropylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

35 1-[3-[(2-Dibutylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-Dimethylaminoethyl)methylcarbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-Dimethylaminopropyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-Pyridylmethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

5 1-[3-[(3-Dimethylamino-2-propyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-(N-Methyl-N-phenyl)ethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-(4-Dimethylamino-1-oxobutyl)phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

10 1-[3-(N-methylpiperazinylcarbonyl)phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-Piperid-1-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

15 1-[3-[(2-Morpholin-4-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(N-Ethylpyrrolidin-2-ylmethyl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-Pyrrolidin-1-ylethyl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

20 1-[3-[(N-Benzylpyrrolidin-3-yl)carbamoyl]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[3-[(2-Dimethylaminomethyl)pyrrolidin-1-yl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline,

25 1-[3-[(3-Dimethylaminopyrrolidin-1-yl)carbamoyl]phenyl carbamoyl]-5-methylthio-6-trifluoromethyl indoline,

1-[2-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,

1-[2-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,

30 1-[3-(2-(Dimethylamino)ethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,

1-[3-(3-(Dimethylamino)propyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,

1-[3-[(2-Dimethylaminoethyl)carbamoyl]phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,

35 1-[4-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,


1-[4-(Dimethylamino)ethyl]phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
 1-[3-(Dimethylaminomethyl)phenylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
 5 1-[3-(Dimethylamino)propyloxy]phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
 1-[3-[(2-Dimethylamino)ethoxy]iminomethyl]phenylcarbamoyl-5-methylthio-6-trifluoromethyl indoline,  
 1-[Phenylcarbamoyl]-5-methylthio-6-trifluoromethyl indoline,  
 10 1-(4-Hydroxymethylphenylcarbamoyl)-5-methylthio-6-trifluoromethyl indoline,  
 1-[(5-Bromo-2-thienyl)carbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
 1-[2-Thienylcarbamoyl]-5-methoxy-6-trifluoromethyl indoline,  
 and pharmaceutically acceptable salts thereof.

7. A compound according to any one of claims 1 to 6 for use in therapy.

15 8. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier or excipient.

9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:  
 the coupling of a compound of formula (II);

20



with a compound of formula (III);

25



wherein P is as defined in formula (I), A and B contain the appropriate functional group(s) necessary to form the moiety  $-NR^{2'}CO$  when coupled, the variables R', R<sup>1'</sup> and R<sup>3'</sup> are R, R<sup>1</sup> and R<sup>3</sup> respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any R', R<sup>1'</sup> and R<sup>3'</sup>, when other than R, R<sup>1</sup> and R<sup>3</sup> respectively to R', R<sup>1</sup> and R<sup>3</sup>, interconverting R, R<sup>1</sup> and R<sup>3</sup> and forming a pharmaceutically acceptable salt thereof.

35



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C07D 209/08, A61K 31/40, C07D 403/12, 401/12, 413/12		A3	(11) International Publication Number: <b>WO 96/23769</b>  (43) International Publication Date: 8 August 1996 (08.08.96)
(21) International Application Number: PCT/EP96/00369		(74) Agent: SUMMERSELL, Richard, John; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).	
(22) International Filing Date: 24 January 1996 (24.01.96)		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 9502051.7 2 February 1995 (02.02.95) GB 9510254.7 20 May 1995 (20.05.95) GB		<p><b>Published</b>  <i>With international search report.</i>  <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(88) Date of publication of the international search report: 24 October 1996 (24.10.96)	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): GASTER, Laramie, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). WYMAN, Paul, Adrian [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). MULHOLLAND, Keith, Raymond [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). DAVIES, David, Thomas [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).			

(54) Title: HETEROCYCLIC COMPOUNDS POSSESSING 5HT<sub>2C</sub> RECEPTOR ANTAGONIST ACTIVITY

## (57) Abstract

The invention relates to heterocyclic families of compounds having pharmacological activity, in particular possessing 5HT<sub>2C</sub> receptor antagonist activity processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 96/00369A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D209/08 A61K31/40 C07D403/12 C07D401/12 C07D413/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 01976 A (SMITHKLINE BEECHAM PLC ;HAM PETER (GB); JONES GRAHAM ELGIN (GB); F) 19 January 1995 cited in the application * overlapping chemical formula * see the whole document ---	1-9
Y	WO 94 14801 A (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); MARTIN ROGER THOM) 7 July 1994 see the whole document ---	1-9
Y	WO 94 04533 A (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); MARTIN ROGER THOM) 3 March 1994 see the whole document ---	1-9

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

1

Date of the actual completion of the international search

31 May 1996

Date of mailing of the international search report

10.09.96

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.  
Fax (+ 31-70) 340-3016

Authorized officer

Stellmach, J

## INTERNATIONAL SEARCH REPORT

International Application No  
PL, EP 96/00369

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 22871 A (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); MARTIN ROGER THOM) 13 October 1994 see the whole document ---	1-9
Y	US 4 428 881 A (HEDRICH LOREN W ET AL) 31 January 1984 see the whole document ---	1-9
P,Y	WO 95 29177 A (SMITHKLINE BEECHAM PLC ;KING FRANCIS DAVID (GB); HAM PETER (GB); F) 2 November 1995 see the whole document ---	1-9
P,Y	WO 95 21844 A (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); JONES GRAHAM ELGI) 17 August 1995 see the whole document ---	1-9
P,Y	J.MED.CHEM., vol. 38, no. 14, 7 July 1995, WASHINGTON, pages 2524-2530, XP002004205 FORBES, I.T.: "5-Methyl-1-(3-Pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: A Novel 5-HT <sub>2c</sub> /5HT <sub>2b</sub> Receptor Antagonist with Improved Affinity, Selectivity, and Oral Activity" see the whole document ----	1-9
E	WO 96 02537 A (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); JONES GRAHAM ELGI) 1 February 1996 see the whole document -----	1-9

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/00369

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: 1-9 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
**PLEASE SEE ATTACHED SHEET!**
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1-9(partially) Phenylcarbamoyl indoline derivatives
2. Claims 1-9(partially) Hetero-carbamoyl indoline derivatives

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
**1-9(partially)**

Remarks on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

1. Phenylcarbamoyl indoline derivatives and their analogues and isosteres ( see the preferred definition of R<sup>3</sup> in the paragraph bridging pages 3/4 and formula (i) for R<sup>3</sup> in claim 1 and the dependant claims 2-9 )
2. Heteroaryl-carbamoyl indoline derivatives and their analogues and isosteres ( see the definition of P in claim 1 and the respective definitions for R<sup>3</sup>, formula (i), (ii) and (iii) and the dependant claims 2-9 )

iii) Incomplete Search

2. Obscurities, inconsistencies, contradictions:

2.2 Lack of conciseness, Incomplete Search:

The chemical formula (I) of claim 1 only contains a minor fixed part and displays a too large number of variables, which may also contain variables. Consequently, the scope of the claims cannot be evaluated and an exhaustive and complete search is thus not possible.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT, EP 96/00369

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9501976	19-01-95	AU-B-	7228394	06-02-95
		CA-A-	2166624	19-01-95
		EP-A-	0707581	24-04-96
WO-A-9414801	07-07-94	NONE		
WO-A-9404533	03-03-94	AU-B-	4704693	15-03-94
		CA-A-	2142721	03-03-94
		CN-A-	1086819	18-05-94
		EP-A-	0656003	07-06-95
		JP-T-	8500580	23-01-96
		NZ-A-	254785	26-09-95
		SI-A-	9300438	31-03-94
		ZA-A-	9306050	20-02-95
WO-A-9422871	13-10-94	EP-A-	0691973	17-01-96
US-A-4428881	31-01-84	NONE		
WO-A-9529177	02-11-95	NONE		
WO-A-9521844	17-08-95	NONE		
WO-A-9602537	01-02-96	NONE		

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**